Intuitive Surgical (NASDAQ:ISRG) Stock: Insider Mark Brosius Sells 61 Shares

Posted by Brenda Bartman on Oct 30th, 2026

Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) EVP Mark Brosius sold 61 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $441.60, for a total value of $26,937.60. Following the sale, the executive vice president directly owned 581 shares of the company’s stock, valued at $256,569.60. This represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

On Monday, October 26th, Mark Brosius sold 61 shares of Intuitive Surgical stock. The shares were sold at an average price of $451.75, for a total value of $27,556.75.
On Friday, September 11th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $365.79, for a total value of $9,144.75.
On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The shares were sold at an average price of $350.20, for a total value of $8,054.60.
On Tuesday, September 8th, Mark Brosius sold 46 shares of Intuitive Surgical stock. The stock was sold at an average price of $361.23, for a total transaction of $16,616.58.
On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89.
On Wednesday, August 19th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $394.26, for a total transaction of $30,358.02.
On Monday, August 17th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $390.67, for a total transaction of $30,081.59.
On Friday, July 31st, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $351.00, for a total value of $9,828.00.

Intuitive Surgical Stock Up 1.0%

ISRG stock opened at $448.76 on Friday. The firm has a market cap of $155.56 billion, a PE ratio of 54.26, a P/E/G ratio of 3.06 and a beta of 1.46. The business has a 50 day moving average of $400.39 and a 200-day moving average of $434.76. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last released its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The business’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.40 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Institutional Trading of Intuitive Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Gerber Kawasaki Wealth & Investment Management raised its position in shares of Intuitive Surgical by 6.4% in the third quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,807 shares of the medical equipment provider’s stock worth $1,141,000 after buying an additional 170 shares in the last quarter. GraniteShares Advisors LLC grew its position in Intuitive Surgical by 4.8% during the third quarter. GraniteShares Advisors LLC now owns 2,601 shares of the medical equipment provider’s stock worth $1,058,000 after buying an additional 118 shares in the last quarter. BOCHK Asset Management Ltd grew its position in Intuitive Surgical by 64.6% during the third quarter. BOCHK Asset Management Ltd now owns 10,700 shares of the medical equipment provider’s stock worth $4,351,000 after buying an additional 4,200 shares in the last quarter. Blue Bell Private Wealth Management LLC increased its stake in Intuitive Surgical by 164.6% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 434 shares of the medical equipment provider’s stock worth $176,000 after acquiring an additional 270 shares during the last quarter. Finally, Greenfield Seitz Capital Management LLC increased its stake in Intuitive Surgical by 56.1% in the 3rd quarter. Greenfield Seitz Capital Management LLC now owns 22,096 shares of the medical equipment provider’s stock worth $8,985,000 after acquiring an additional 7,945 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ISRG. Oppenheimer reissued an “outperform” rating and set a $500.00 target price on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Wall Street Zen cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. BTIG Research reiterated a “buy” rating and issued a $454.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. Finally, Truist Financial reduced their price objective on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $493.54.

Check Out Our Latest Stock Analysis on Intuitive Surgical

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Intuitive Surgical reported quarterly revenue of $3.05 billion, above the $2.91 billion consensus estimate, and earnings of $3.00 per share versus expectations of $2.65. The earnings beat supports the long-term growth outlook for its robotic-surgery platforms. ISRG Sales Growth Article
Positive Sentiment: Analyst sentiment remains favorable. ISRG carries a “Moderate Buy” consensus rating, with an average price target of $493.54; Baird raised its target to $550 and maintained an outperform rating, while other firms reiterated bullish views.
Positive Sentiment: Institutional ownership is high at 83.64%, and several large investors—including Bank of America, Amundi, Arrowstreet Capital and Janus Henderson—recently increased their positions, providing a supportive ownership backdrop.
Neutral Sentiment: Investors are weighing whether ISRG’s premium valuation is justified. The stock has rebounded over the past one to three months but remains below its prior-year level, leaving the sustainability of procedure growth and earnings estimates as key issues.
Negative Sentiment: Profitability remains a concern: commentary pointed to lower net income and earnings per share despite higher revenue, indicating margin pressure. With the shares trading at a high earnings multiple, any slowdown in procedures, pricing or margins could create volatility.
Negative Sentiment: Several insiders reported sales, including former CEO Gary Guthart, Fredrik Widman and EVP Mark Brosius. Brosius sold shares in two transactions, while Guthart’s sale was substantially larger. The trades were conducted under pre-arranged Rule 10b5-1 plans, reducing their signaling value, but the selling may weigh modestly on sentiment. ISRG Insider Sales

About Intuitive Surgical

(Get Free Report)

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.